Protocol Ledger

NCT05767047 · Phase III · RECRUITING

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Interventional Phase III clinical trial protocol NCT05767047 sponsored by Amgen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-23 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05767047
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05767047
Protocol FieldVerified Registry Value
NCT IdentifierNCT05767047
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2023-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05767047
Hospital Research SiteLocationSite Profile
Meir Medical CenterKfar Saba, IsraelOpen Hospital Dossier ->
Hospital Universitari i Politecnic La FeValencia, SpainOpen Hospital Dossier ->
Hospital Universitario Ramon y CajalMadrid, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI